IVERIC bio Inc

NASDAQ:ISEEUnited States

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Contact Information

Headquarters

8 SYLVAN WAY, Suite 2372PARSIPPANY, NJ, United States 07054

Phone

609-474-6755

Fax

302-655-5049

Executives

Independent Chairman of the Board

Adrienne Graves

President, Director

Pravin Dugel

Chief Executive Officer, Director

Glenn Sblendorio

Chief Financial Officer, Senior Vice President, Treasurer

David Carroll

Chief Operating Officer, Senior Vice President

Keith Westby